Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.79 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.79 |
| ▸ | FNTA | P49354 | 7/20 | 0.57 |
| ▸ | FNTB | P49356 | 7/20 | 0.57 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3625451 | 0.99 | CYP11B1 (0.77) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8303322 | 0.94 | CYP11B1 (0.72) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL31472005 | 0.84 | CYP11B1 (0.62) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL31471987 | 0.84 | CYP11B1 (0.62) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7259729 | 0.83 | CYP11B1 (0.61) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7163166 | 0.82 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8302850 | 0.82 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL6409239 | 0.81 | CYP11B1 (0.54) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7194363 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7086608 | 0.81 | CYP11B1 (0.79) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| EP-1200430-A4 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORP LTD (KR) | 2003-01-22 | — | — | EP | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6384061-B1 | HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS | LG CHEMICAL LTD. (KR) | 2002-05-07 | — | — | US | disclosed |
| EP-1200430-A1 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION, LTD. (KR) | 2002-05-02 | — | — | EP | disclosed |
| US-6358956-B1 | IMIDAZOLYLALKYL-1-PIPERAZINE DERIVATIVES; FARNESYL-PROTEIN AND GERANYLGERANYL TRANSFERASE INHIBITORS; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0900081-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0841919-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0891357-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0877610-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-11-18 | — | — | EP | disclosed |
| EP-0841919-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997036591-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036898-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027853-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | CYP11B1 530/4885CYP11B2 621/4885FNTA 4/4885 |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | CYP11B1 74/4885CYP11B2 110/4885FNTA 1/4885 |
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | CYP11B1 515/4885CYP11B2 578/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.